In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow

In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow

Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone m...

Full description

Bibliographic Details
Main Authors:	P.B. Soares, T.S. Jeremias, M. Alvarez-Silva, M.A. Licinio, M.C. Santos-Silva, C.L. Vituri
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2013-01-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Bone marrow stromal cell Hematopoietic progenitors Imatinib mesylate Myelosuppression
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000100039&lng=en&tlng=en

Similar Items

by: P.B. Soares, et al.
Published: (2013-01-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01)

Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
by: Shen H, et al.
Published: (2019-12-01)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
by: Abbas Agaimy, et al.
Published: (2013-03-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
by: Chaoyong Shen, et al.
Published: (2014-11-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib
by: Mukul Vij, et al.
Published: (2013-01-01)

Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
by: Eun Hyea Park, et al.
Published: (2018-12-01)

A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate
by: E. B. Myakoshina, et al.
Published: (2020-09-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
by: Jing Liu, et al.
Published: (2017-03-01)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
by: Min Kyu Kang, et al.
Published: (2019-05-01)

Soft Tissue Calcification Secondary to Imatinib Mesylate in a Patient with Gastrointestinal Stromal Tumor
by: Enck, Robert E., et al.
Published: (2013)

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report
by: Clara Saldarriaga, et al.
Published: (2008-12-01)

An audit of gastrointestinal stromal tumors from a tertiary medical college hospital in Eastern India
by: Samrat Dutta, et al.
Published: (2018-01-01)

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery
by: Xu H, et al.
Published: (2021-02-01)

Successful Surgical Resection of Advanced Gastrointestinal Stromal Tumor Post Neoadjuvent Therapy
by: SM Kamil, et al.
Published: (2009-01-01)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01)

Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient
by: Hye-Jin Kim, et al.
Published: (2020-10-01)

Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants
by: Gholamreza Azizi, et al.
Published: (2014-06-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
by: Fabio Morandi, et al.
Published: (2018-09-01)

The role of c-kit and imatinib mesylate in uveal melanoma
by: Pereira Patricia, et al.
Published: (2005-10-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

Gastrointestinal stromal tumor of gastric origin: case report
by: Ayder Anselmo Gomes Vivi, et al.
Published: (2017-06-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)